Recent News

• 09.15.2026 - Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
• 08.19.2026 - Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
• 04.16.2026 - Femasys Shareholder Update – Q1 2026
• 10.29.2025 - Meet the metro Atlanta woman who invented a new permanent birth control
• 07.15.2025 - Transforming women’s health: The power of Femtech and minimally invasive solutions
• 06.26.2025 - Intratubal insemination: Another Option in Fertility Treatment
• 03.04.2025 - Femasys Offers a Fresh Take on Women’s Reproductive Healthcare
• 01.30.2025 - Disrupting Stagnant Women’s Reproductive Health Ecosystem with Safer More Accessible Options with Kathy Lee-Sepsick Femasys
• 01.30.2025 - Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
• 11.26.2024 - Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Recent Filings

• 09.03.2026 - S-3 Registration statement under Securities Act of 1933
• 08.31.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.20.2026 - D Notice of Exempt Offering of Securities
• 08.17.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 08.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2026 - 8-K Current report
• 08.14.2026 - EX-99.1 EX-99.1
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2026 - 4 Statement of changes in beneficial ownership of securities